Metrics as of 10/17/2026, 08:41 AM (Berlin time), refresh in progress.
Armata Pharmaceuticals Stock
Armata Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Deborah L. Birx
- Employees
- 61
- Market cap
- $125 M
- IPO
- 20/05/1994
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing…
Armata Pharmaceuticals stock: price history
1D
+9.1%
1W
-7.2%
1M
-17.2%
6M
-70.7%
YTD
-46.3%
1Y
-3.4%
2Y
+40.4%
5Y
-2.3%
10Y
-98.3%
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~4% weaker price swings than usual
Ask the agents about Armata Pharmaceuticals
Analyst assessment of Armata Pharmaceuticals
PRICE TARGET LOW
US$15.00
CONSENSUS
US$15.00
MEDIAN
US$15.00
PRICE TARGET HIGH
US$15.00
0
STRONG BUY
4
BUY
0
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 23/09/2026
Armata Pharmaceuticals stock metrics
P/E
-0.64
P/B
-0.54
EV/EBITDA
-2.46
RETURN ON EQUITY
-32.1%
NET MARGIN
2,953.8%
DEBT/EQUITY
-1.36
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
31.1%
FLOAT SHARES
11,577,880
AVG. DAILY VOLUME (30D)
291,632
Insider transactions (SEC)
Birx Deborah
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Armata Pharmaceuticals stock
What does Armata Pharmaceuticals do?
Armata Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Deborah L. Birx, the company employs around 61 people.
The IPO was on 20/05/1994; the stock trades on AMEX under the ticker ARMP.
What do analysts say about Armata Pharmaceuticals stock?
4 analysts rate the stock, the consensus is Buy (as of 23/09/2026).
The average price target is US$15.00, ranging from US$15.00 to US$15.00, with a median of US$15.00.
This is an external assessment, not a statement by Market Jury.
When does Armata Pharmaceuticals report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -4% stronger than usual.
Does Armata Pharmaceuticals pay a dividend?
No, Armata Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Armata Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Armata Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Armata Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.